2 weeks Ago By ABMN Staff
Maverick Capital Ltd. lifted its holdings in shares of Humana Inc. ( NYSE:HUM – Free Report ) by 41.
0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 191,570 shares of the insurance provider’s stock after purchasing an additional 55,733 shares during the quarter. Humana accounts for approximately 1.
4% of Maverick Capital Ltd.’s portfolio, making the stock its 26th largest position. Maverick Capital Ltd.
owned about 0.16% of Humana worth $71,580,000 as of its most recent SEC filing. Several other institutional investors also recently modified their holdings of HUM.
MBB Public Markets I LLC grew its stake in Humana by 8.5% in the 2nd quarter. MBB Public Markets I LLC now owns 119,760 shares of the insurance provider’s stock worth $44,748,000 after buying an additional 9,430 shares in the last quarter.
Daymark Wealth Partners LLC lifted its holdings in shares of Humana by 41.6% during the 2nd quarter. Daymark Wealth Partners LLC now owns 1,466 shares of the insurance provider’s stock worth $548,000 after acquiring an additional 431 shares during the last quarter.
Earnest Partners LLC grew its position in Humana by 5.8% in the second quarter. Earnest Partners LLC now owns 50,928 shares of the insurance provider’s stock worth $19,029,000 after acquiring an additional 2,799 shares in the last quarter.
APG Asset Management US Inc. increased its stake in Humana by 3.0% in the second quarter.
APG Asset Management US Inc. now owns 67,669 shares of the insurance provider’s stock valued at $25,274,000 after acquiring an additional 1,955 shares during the last quarter. Finally, AXA S.
A. raised its position in Humana by 285.1% during the second quarter.
AXA S.A. now owns 50,809 shares of the insurance provider’s stock valued at $18,985,000 after purchasing an additional 37,614 shares in the last quarter.
92.38% of the stock is currently owned by institutional investors. Humana Price Performance Shares of HUM stock opened at $313.
04 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.
66 and a current ratio of 1.66. Humana Inc.
has a fifty-two week low of $298.61 and a fifty-two week high of $530.54.
The firm has a market cap of $37.72 billion, a P/E ratio of 19.49, a P/E/G ratio of 2.
44 and a beta of 0.50. The business’s 50 day moving average price is $352.
81 and its 200-day moving average price is $344.87. Humana Announces Dividend The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th.
Shareholders of record on Monday, September 30th will be issued a $0.885 dividend. The ex-dividend date is Monday, September 30th.
This represents a $3.54 annualized dividend and a yield of 1.13%.
Humana’s dividend payout ratio (DPR) is presently 22.04%. Wall Street Analyst Weigh In A number of equities analysts have recently issued reports on the company.
JPMorgan Chase & Co. upped their price objective on Humana from $332.00 to $396.
00 and gave the stock a “neutral” rating in a report on Wednesday, August 21st. Royal Bank of Canada upped their target price on Humana from $385.00 to $400.
00 and gave the stock an “outperform” rating in a research note on Thursday, September 5th. Baird R W raised shares of Humana to a “hold” rating in a research note on Thursday, May 30th. TD Cowen boosted their price objective on shares of Humana from $396.
00 to $407.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Finally, Morgan Stanley assumed coverage on shares of Humana in a report on Monday, June 24th.
They set an “equal weight” rating and a $374.00 target price on the stock. Thirteen research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock.
Based on data from MarketBeat, Humana presently has a consensus rating of “Hold” and a consensus target price of $398.70. View Our Latest Analysis on HUM Humana Company Profile ( Free Report ) Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States.
It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Recommended Stories Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter ..
